Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

Abstract Neuroinflammation is considered one of the cardinal features of Alzheimer’s disease (AD). Neuritic plaques composed of amyloid β and neurofibrillary tangle-laden neurons are surrounded by reactive astrocytes and microglia. Exposure of microglia, the resident myeloid cell of the CNS, to amyl...

Full description

Bibliographic Details
Main Authors: Dawling A. Dionisio-Santos, John A. Olschowka, M. Kerry O’Banion
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Journal of Neuroinflammation
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12974-019-1453-0
_version_ 1819108551746912256
author Dawling A. Dionisio-Santos
John A. Olschowka
M. Kerry O’Banion
author_facet Dawling A. Dionisio-Santos
John A. Olschowka
M. Kerry O’Banion
author_sort Dawling A. Dionisio-Santos
collection DOAJ
description Abstract Neuroinflammation is considered one of the cardinal features of Alzheimer’s disease (AD). Neuritic plaques composed of amyloid β and neurofibrillary tangle-laden neurons are surrounded by reactive astrocytes and microglia. Exposure of microglia, the resident myeloid cell of the CNS, to amyloid β causes these cells to acquire an inflammatory phenotype. While these reactive microglia are important to contain and phagocytose amyloid plaques, their activated phenotype impacts CNS homeostasis. In rodent models, increased neuroinflammation promoted by overexpression of proinflammatory cytokines can cause an increase in hyperphosphorylated tau and a decrease in hippocampal function. The peripheral immune system can also play a detrimental or beneficial role in CNS inflammation. Systemic inflammation can increase the risk of developing AD dementia, and chemokines released directly by microglia or indirectly by endothelial cells can attract monocytes and T lymphocytes to the CNS. These peripheral immune cells can aid in amyloid β clearance or modulate microglia responses, depending on the cell type. As such, several groups have targeted the peripheral immune system to modulate chronic neuroinflammation. In this review, we focus on the interplay of immunomodulating factors and cell types that are being investigated as possible therapeutic targets for the treatment or prevention of AD.
first_indexed 2024-12-22T03:11:44Z
format Article
id doaj.art-df43ab8fa06d4c18897474e58f70aada
institution Directory Open Access Journal
issn 1742-2094
language English
last_indexed 2024-12-22T03:11:44Z
publishDate 2019-04-01
publisher BMC
record_format Article
series Journal of Neuroinflammation
spelling doaj.art-df43ab8fa06d4c18897474e58f70aada2022-12-21T18:40:55ZengBMCJournal of Neuroinflammation1742-20942019-04-0116111310.1186/s12974-019-1453-0Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s diseaseDawling A. Dionisio-Santos0John A. Olschowka1M. Kerry O’Banion2Department of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and DentistryDepartment of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and DentistryDepartment of Neuroscience, Del Monte Institute for Neuroscience, University of Rochester School of Medicine and DentistryAbstract Neuroinflammation is considered one of the cardinal features of Alzheimer’s disease (AD). Neuritic plaques composed of amyloid β and neurofibrillary tangle-laden neurons are surrounded by reactive astrocytes and microglia. Exposure of microglia, the resident myeloid cell of the CNS, to amyloid β causes these cells to acquire an inflammatory phenotype. While these reactive microglia are important to contain and phagocytose amyloid plaques, their activated phenotype impacts CNS homeostasis. In rodent models, increased neuroinflammation promoted by overexpression of proinflammatory cytokines can cause an increase in hyperphosphorylated tau and a decrease in hippocampal function. The peripheral immune system can also play a detrimental or beneficial role in CNS inflammation. Systemic inflammation can increase the risk of developing AD dementia, and chemokines released directly by microglia or indirectly by endothelial cells can attract monocytes and T lymphocytes to the CNS. These peripheral immune cells can aid in amyloid β clearance or modulate microglia responses, depending on the cell type. As such, several groups have targeted the peripheral immune system to modulate chronic neuroinflammation. In this review, we focus on the interplay of immunomodulating factors and cell types that are being investigated as possible therapeutic targets for the treatment or prevention of AD.http://link.springer.com/article/10.1186/s12974-019-1453-0Alzheimer’s diseaseMicrogliaCytokinesInnate immunityAdaptive immunityTherapeutics
spellingShingle Dawling A. Dionisio-Santos
John A. Olschowka
M. Kerry O’Banion
Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Journal of Neuroinflammation
Alzheimer’s disease
Microglia
Cytokines
Innate immunity
Adaptive immunity
Therapeutics
title Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
title_full Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
title_fullStr Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
title_full_unstemmed Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
title_short Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
title_sort exploiting microglial and peripheral immune cell crosstalk to treat alzheimer s disease
topic Alzheimer’s disease
Microglia
Cytokines
Innate immunity
Adaptive immunity
Therapeutics
url http://link.springer.com/article/10.1186/s12974-019-1453-0
work_keys_str_mv AT dawlingadionisiosantos exploitingmicroglialandperipheralimmunecellcrosstalktotreatalzheimersdisease
AT johnaolschowka exploitingmicroglialandperipheralimmunecellcrosstalktotreatalzheimersdisease
AT mkerryobanion exploitingmicroglialandperipheralimmunecellcrosstalktotreatalzheimersdisease